Clinical TrialID 7752

Sitagliptin in Combination With Beidougen Capsule for Type 2 Diabetes

NCT05667220

Type 2 Diabetes

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Formula: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
7752
Evidence Id
7752
Core Evidence Id
7752
Source Clinical Trial Id
7747
Herb2 Clinical Trial Id
HBCT007747
Nct Id
NCT05667220
Title
Sitagliptin in Combination With Beidougen Capsule for Type 2 Diabetes
Status
Recruiting
Phase
Phase 4
Study Result
No
Study Condition
Type 2 Diabetes
Study Type
Interventional
Study Design
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
Intervention
DRUG: Sitagliptin|DRUG: Sitagliptin combined with Beidougen capsule
Intervention Allocation
Non_Randomized
Intervention Model
Parallel
Intervention Mask
Intervention Purpose
Basic_Science
Gender
All
Age
Adult, Older_Adult
Enrollment
20
Outcome Measure
Fasting blood glucose change, Fasting blood glucose (FBG) levels (mmol/L) were analyzed by an autoanalyzer (Hitachi 747, Roche Diagnostics, Germany) at the Central Chemistry Laboratory of Beijing Chaoyang Hospital affiliated with Capital Medical University., Changes in fasting blood glucose from baseline to 1 week treatment
Sponsor Collaborator
Beijing Chao Yang Hospital
Funded By
OTHER
Location
Beijing Chao-yang Hospital, Capital Medical University, Beijing, Beijing, 100020, China
Other Id
2022-Sitagliptin-Beidougen
Start Date
2022-12-01
Primary Completion Date
2023-10-31
Completion Date
2023-12-31
First Posted
2022-12-28
Results First Posted
Last Update Posted
2023-01-03
Study Document
Study Url
https://clinicaltrials.gov/study/NCT05667220
Title Cn
Title En
Sitagliptin in Combination With Beidougen Capsule for Type 2 Diabetes
Bilingual Status
semi_complete